Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,812.70 | 70.80 | 0.81% |
| CAC 40 | 7,804.33 | 12.86 | 0.17% |
| DAX 40 | 23,987.56 | 186.76 | -0.77% |
| Dow JONES (US) | 42,860.67 | 98.91 | 0.23% |
| FTSE 100 | 8,853.08 | 20.80 | 0.24% |
| HKSE | 24,162.87 | 18.56 | -0.08% |
| NASDAQ | 19,706.04 | 114.80 | 0.59% |
| Nikkei 225 | 38,211.51 | 122.94 | 0.32% |
| NZX 50 Index | 12,564.42 | 25.16 | 0.20% |
| S&P 500 | 6,036.20 | 30.32 | 0.50% |
| S&P/ASX 200 | 8,587.20 | 71.50 | 0.84% |
| SSE Composite Index | 3,384.82 | 14.96 | -0.44% |